KR20230131189A - Tead 억제제 및 이의 용도 - Google Patents

Tead 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20230131189A
KR20230131189A KR1020237021880A KR20237021880A KR20230131189A KR 20230131189 A KR20230131189 A KR 20230131189A KR 1020237021880 A KR1020237021880 A KR 1020237021880A KR 20237021880 A KR20237021880 A KR 20237021880A KR 20230131189 A KR20230131189 A KR 20230131189A
Authority
KR
South Korea
Prior art keywords
increased
cancer
activity
tead
compound
Prior art date
Application number
KR1020237021880A
Other languages
English (en)
Korean (ko)
Inventor
알프레도 시. 카스트로
마이클 버크
Original Assignee
이케나 온콜로지, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이케나 온콜로지, 인코포레이티드 filed Critical 이케나 온콜로지, 인코포레이티드
Publication of KR20230131189A publication Critical patent/KR20230131189A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237021880A 2020-12-02 2021-12-02 Tead 억제제 및 이의 용도 KR20230131189A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063120441P 2020-12-02 2020-12-02
US63/120,441 2020-12-02
PCT/US2021/072684 WO2022120354A1 (fr) 2020-12-02 2021-12-02 Inhibiteurs de tead et utilisations associées

Publications (1)

Publication Number Publication Date
KR20230131189A true KR20230131189A (ko) 2023-09-12

Family

ID=79283210

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237021880A KR20230131189A (ko) 2020-12-02 2021-12-02 Tead 억제제 및 이의 용도

Country Status (8)

Country Link
EP (1) EP4255895A1 (fr)
JP (1) JP2023553866A (fr)
KR (1) KR20230131189A (fr)
CN (1) CN117015531A (fr)
AU (1) AU2021392040A1 (fr)
CA (1) CA3200814A1 (fr)
IL (1) IL303376A (fr)
WO (1) WO2022120354A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
TW202108571A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
WO2023060227A1 (fr) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Inhibiteurs de tead et utilisations associées
WO2023173053A1 (fr) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
WO2023173057A1 (fr) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
WO2023230205A1 (fr) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
WO2024077085A1 (fr) * 2022-10-07 2024-04-11 Memorial Sloan-Kettering Cancer Center Ciblage de la phospholipase a2 (pla2) dans le cancer
WO2024092116A1 (fr) 2022-10-26 2024-05-02 Ikena Oncology, Inc. Association d'inhibiteurs de tead et d'inhibiteurs d'egfr et utilisations associées
WO2024105610A1 (fr) 2022-11-18 2024-05-23 Novartis Ag Combinaisons pharmaceutiques et leurs utilisations

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3120564A (en) * 1960-01-13 1964-02-04 American Cyanamid Co Alkenoylamino benzophenones
ZA825719B (en) * 1981-09-03 1983-06-29 Recordati Chem Pharm Alkanoylanilides
JPS58179838A (ja) * 1982-04-14 1983-10-21 Konishiroku Photo Ind Co Ltd 画像形成方法
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CN1310907C (zh) 2001-04-27 2007-04-18 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤药
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (fr) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Promedicaments d'inhibiteurs de pi-3 kinase
JP4980715B2 (ja) 2003-05-30 2012-07-18 ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド がんまたはウイルス疾患を治療するための三環性複素環化合物、組成物および方法
EP1692153A4 (fr) 2003-07-03 2007-03-21 Univ Pennsylvania Inhibition de l'expression d'une syk kinase
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
BRPI0511967B8 (pt) 2004-06-11 2021-05-25 Japan Tobacco Inc derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN1944398A (zh) * 2005-01-11 2007-04-11 中国医学科学院药物研究所 新的苯甲酰胺类化合物及其制法和药物用途
EP2161275A1 (fr) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Promédicaments de composés de 2,4-pyrimidinédiamine et leurs utilisations
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
JP5132550B2 (ja) 2005-05-12 2013-01-30 アボット・ラボラトリーズ アポトーシス促進剤
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA3201163A1 (fr) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
EA019255B1 (ru) 2005-10-07 2014-02-28 Экселиксис, Инк. Ингибиторы фосфатидилинозит-3-киназы и содержащие их фармацевтические композиции
BRPI0618179A2 (pt) 2005-11-01 2011-08-23 Targegen Inc inibidores de biaril meta pirimidina de cinases
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2650303C (fr) 2006-04-26 2015-03-24 F. Hoffmann-La Roche Ag Composes pharmaceutiques de thienopyrimidine et leur utilisation
EP2081435B1 (fr) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
PL2152701T3 (pl) 2007-03-12 2016-10-31 Związki fenyloaminopirymidyny i ich zastosowania
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
CN102026999B (zh) 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
CA2778115C (fr) 2009-10-28 2016-04-05 Newlink Genetics Corporation Derives imidazole comme inhibiteurs de l'ido
ES2557454T3 (es) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización
EP2542588A1 (fr) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Anticorps contre le csf-1r humain et leurs utilisations
RS58211B1 (sr) 2010-05-04 2019-03-29 Five Prime Therapeutics Inc Antitela koja vezuju csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (fr) 2011-04-15 2018-03-17
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
WO2013087699A1 (fr) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
WO2013119716A1 (fr) 2012-02-06 2013-08-15 Genentech, Inc. Compositions et procédés d'utilisation d'inhibiteurs de csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP3539984A1 (fr) 2012-05-11 2019-09-18 Five Prime Therapeutics, Inc. Procédés de traitement de maladies avec des anticorps qui se lient au récepteur 1 du facteur de stimulation de colonie (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RU2718751C2 (ru) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
DK2986611T3 (da) 2013-04-18 2019-05-06 Shanghai Fochon Pharmaceutical Co Ltd Bestemte proteinkinaseinhibitorer
WO2016035008A1 (fr) 2014-09-04 2016-03-10 Lupin Limited Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
CA2981886A1 (fr) 2015-04-16 2016-10-20 Icahn School Of Medicine At Mount Sinai Antagonistes de la kinase ksr
TWI804498B (zh) * 2017-06-23 2023-06-11 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
US11524943B1 (en) * 2017-12-06 2022-12-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
WO2020081572A1 (fr) * 2018-10-15 2020-04-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs du facteur de transcription à domaine associé transcriptionnel amélioré (tead) et leurs utilisations
US20210403415A1 (en) * 2018-10-26 2021-12-30 The Trustees Of Indiana University Compounds and methods to attenuate tumor progression and metastasis
WO2020125747A1 (fr) 2018-12-21 2020-06-25 基石药业（苏州）有限公司 Forme cristalline et forme amorphe d'inhibiteur de mek et leurs applications
WO2020243423A1 (fr) * 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
CN114728905A (zh) * 2019-11-13 2022-07-08 基因泰克公司 治疗性化合物及使用方法
WO2021142345A1 (fr) 2020-01-08 2021-07-15 Icahn School Of Medicine At Mount Sinai Modulateurs à petites molécules de mek liant ksr
BR112022013593A2 (pt) 2020-01-10 2022-09-13 Immuneering Corp Inibidores de mek e usos terapêuticos dos mesmos
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral

Also Published As

Publication number Publication date
IL303376A (en) 2023-08-01
WO2022120354A1 (fr) 2022-06-09
EP4255895A1 (fr) 2023-10-11
JP2023553866A (ja) 2023-12-26
AU2021392040A1 (en) 2023-06-29
CN117015531A (zh) 2023-11-07
AU2021392040A9 (en) 2024-02-08
CA3200814A1 (fr) 2022-06-09

Similar Documents

Publication Publication Date Title
US11760728B2 (en) Tead inhibitors and uses thereof
US10624968B2 (en) Compounds for treating cancer
KR20220034739A (ko) Tead 억제제 및 이의 용도
KR20230131189A (ko) Tead 억제제 및 이의 용도
WO2022120355A1 (fr) Agents de dégradation de tead et leurs utilisations
WO2017223243A1 (fr) Inhibiteurs de cxcr4 et leurs utilisations
WO2022120353A1 (fr) Inhibiteurs de tead et leurs utilisations
WO2023114984A1 (fr) Inhibiteurs de tead et leurs utilisations
KR20230172548A (ko) Mek 억제제 및 이의 용도
US11878958B2 (en) MEK inhibitors and uses thereof
US20230233546A1 (en) Methods of treating cancer
WO2023173053A1 (fr) Inhibiteurs de mek et leurs utilisations
WO2023211889A1 (fr) Composés polymorphes et leurs utilisations
WO2023173057A1 (fr) Inhibiteurs de mek et leurs utilisations
WO2022187849A1 (fr) Dérivés de la salinomycine et leurs utilisations
WO2022187520A1 (fr) 3-pipéridinyl-pyrazolo[3,4-b]pyridines substituées et composés apparentés et leur utilisation dans le traitement d'états médicaux